Abiomed Inc (NASDAQ:ABMD) Sellers Reduced By 4.17% Their Shorts

April 17, 2018 - By Eula Gilbert

ABIOMED, Inc. (NASDAQ:ABMD) Corporate Logo

Big Money Sentiment decreased to 1.18 in Q4 2017. It has change of 0.12, from 2017Q3’s 1.3. The ratio is negative due to ABIOMED, Inc. positioning: 19 sold and 110 reduced. 55 funds amassed holdings and 97 increased holdings. Investors holded 38.51 million in 2017Q3 but now own 36.44 million shares or 5.39% less.
New Mexico Educational Retirement Board owns 10,400 shs. Sumitomo Mitsui Asset Management has invested 0.06% in ABIOMED, Inc. (NASDAQ:ABMD). Portolan Cap Management Lc stated it has 22,440 shs. Messner And Smith Theme Value Investment Mgmt Limited Ca reported 6,553 shs or 1.96% of all its holdings. Duncker Streett And Inc holds 0.01% of its capital in ABIOMED, Inc. (NASDAQ:ABMD) for 175 shs. Invest House Limited Co reported 0.09% of its capital in ABIOMED, Inc. (NASDAQ:ABMD). Amp Cap Invsts Ltd owns 15,299 shs. The Massachusetts-based Beaumont Fincl Ptnrs Ltd Company has invested 0.06% in ABIOMED, Inc. (NASDAQ:ABMD). Wells Fargo & Mn reported 245,241 shs. Ci Incorporated reported 25 shs. Loring Wolcott And Coolidge Fiduciary Advsrs Llp Ma has 0% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 8 shs. Dynamic Cap Mgmt Limited invested 0.18% of its capital in ABIOMED, Inc. (NASDAQ:ABMD). 433 were accumulated by Advisory Svcs Ltd. Prudential Inc reported 91,910 shs or 0.02% of all its holdings. Hanseatic Mngmt Ser invested in 0.58% or 3,074 shs.

ABIOMED, Inc. registered $5.41 million net activity with 0 insider purchases and 1 sale since February 20, 2018.

It was registered a decrease on Abiomed Inc (NASDAQ:ABMD)’s shares shorted with 4.17%. FINRA published in April ABMD’s total 1.20M shares shorted. That’s 4.17% down from 1.26 million shares. 3 days will cost ABMD With 453,600 average volume to recover its former position. Abiomed Inc’s shares shorted float is 2.77%.

The stock decreased 0.14% or $0.42 during the last trading session, reaching $296.32.Currently ABIOMED, Inc. is uptrending after 128.67% change in last April 17, 2017. ABMD has also 298,281 shares volume. ABMD outperformed by 117.12% the S&P500.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart.The firm is worth $13.12 billion. It also provides continuum of care to heart failure patients.148.68 is the P/E ratio. The firm offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter axial flow pump.

ABIOMED, Inc. (NASDAQ:ABMD) Ratings Coverage

Total analysts of 8 have positions in Abiomed (NASDAQ:ABMD) as follows: 7 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 88%. The firm has $370.0 highest while $208.0 is the lowest [Target]. The average target $305.13 is 2.97% above the last ($296.32) price. Since November 2, 2017 according to StockzIntelligence Inc Abiomed has 12 analyst reports. The stock rating was maintained by Jefferies with “Buy” on Thursday, December 21. On Thursday, November 2 the stock has “Buy” rating by Jefferies. On Thursday, January 4 Piper Jaffray maintained ABIOMED, Inc. (NASDAQ:ABMD) rating. Piper Jaffray has “Buy” rating and $220.0 target. On Thursday, February 1 the stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given by Jefferies. The company rating was maintained by Morgan Stanley on Friday, February 2. In Thursday, February 1 report Piper Jaffray maintained it with “Buy” rating and $300.0 target. On Friday, February 2 Guggenheim maintained ABIOMED, Inc. (NASDAQ:ABMD) rating. Guggenheim has “Buy” rating and $280.0 target. On Friday, February 2 the firm earned “Buy” rating by Stephens. On Monday, April 9 Stephens maintained the shares of ABMD in report with “Buy” rating. On Friday, February 16 the firm earned “Buy” rating by SunTrust.

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: